DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
GE Vernova - 2 Buster's - 2 Duolingo - 2 General Motors - 2 Bausch - 2 Hakyung Kim - 2 Yun Li - 2 Elliott - 2
Top related locs:
Detroit U.S Stifel Covance Labcorp Fortrea COOs North America
Top related orgs:
JPMorgan - 2 GE - 2 Bank of America - 2 GameStop - 2 General - 2 Square - 2 Veritas Capital - 2 13D - 2

Search resuls for: "Patient Square Capital"


6 mentions found


☆ Stocks making the biggest moves midday: Broadcom, GE Vernova, Stitch Fix, GameStop & more
  + stars: | 2024-12-11 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +5 min
GE Vernova — Shares of the energy equipment maker jumped more than 6% after announcing it would initiate a dividend of 25 cents per share and an initial $6 billion share repurchase authorization. Dave & Buster's posted a loss of 84 cents per share on revenue of $453 million for the third quarter. Analysts surveyed by LSEG anticipated a loss of 37 cents a share and $466 million in revenue. Patterson — The dental and animal health company soared 34% on the back of news that Patterson would be acquired by Patient Square Capital . Stitch Fix — Shares surged 44% after the online personal styling company raised its fiscal second-quarter revenue outlook.
Persons: Pinjalim Bora, Macy's, GE Vernova, Chris Morris, Buster's, LSEG, Duolingo, Patterson, General Motors, Bausch, Merrell, Krispy, — CNBC's Michelle Fox, Alex Harring, Hakyung Kim, Yun Li, Sarah Min, Pia Singh Organizations: Broadcom, Apple, JPMorgan, GE, Buster's Entertainment, Dave, Bank of America, GameStop, Patient Square, General, Citi, Stifel, JetBlue —, Street, Story3 Capital Partners, U.S . Pharmacy, CVS Health, Senate Locations: Detroit, U.S
☆ Stocks making the biggest moves premarket: GameStop, Macy's, GE Vernova, Duolingo and more
  + stars: | 2024-12-11 | by ( Brian Evans | ) www.cnbc.com   time to read: +3 min
GE Vernova — The energy equipment maker fell 2.4% after it issued weaker-than-expected full-year revenue guidance for both the 2024 and 2025 fiscal years. GE Vernova also announced it would initiate a dividend of 25 cents per share and an initial $6 billion share repurchase authorization. Duolingo — Shares of the language learning company slipped by about 2% after a downgrade to neutral from buy at Bank of America. GameStop — The video game retailer saw shares rising more than 3% in premarket trading after the firm reported an unexpected profit in the latest quarter. Stitch Fix also raised the top end of its full-year revenue outlook and now expects $1.14 billion to $1.18 billion.
Persons: GE Vernova, Buster's, Duolingo, FactSet, General Motors, Bausch, Yun Li, Lisa Kailai Han, Hakyung Kim, Michelle Fox, Samantha Subin, Jesse Pound, Spencer Kimball Organizations: GE, Bank of America, GameStop, Google, Patterson, —, Patient Square Capital, General, GM, Citigroup, JPMorgan Locations: Detroit, Stifel
☆ Starboard may be poised to build value amicably at contract research firm Fortrea
  + stars: | 2023-10-21 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +5 min
CROs work with drug companies through all stages of the drug development process, from drug discovery and preclinical development to Phase I through IV post-approval work. With a material portion of that outsourced, the CRO industry has grown accordingly. So, there are strong secular tailwinds driving growth for the CRO industry, but to be a successful contract research organization, it helps to have global scale. With peer margins and peer multiples, Starboard sees this as a $47 to $72 stock. Elliott Management recently partnered with Patient Square Capital and Veritas Capital to acquire Fortrea peer Syneos Health Inc (SYNH) for $7.1 billion.
Persons: Covance, Fortrea, Tom Pike, Pike, Elliott, Ken Squire Organizations: Fortrea, Labcorp, Development, Elliott Management, Square, Veritas Capital, Inc, pharma, 13D, Fortrea Holdings Locations: Covance, Labcorp, Fortrea
☆ Activist Elliott makes inroads at Catalent to build value. Here’s what could happen next
  + stars: | 2023-09-16 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +7 min
This segment also handles the formulation, development and manufacturing for parenteral dose forms, including vials and prefilled syringes. Activist Commentary: Elliott is a very successful and astute activist investor, particularly in the technology sector. While as an activist Elliott will do whatever it feels is necessary to enhance shareholder value, in the past the firm has made significant use of the strategy of offering to acquire its portfolio companies as the best catalyst to enhance shareholder value. Like Catalent, Syneos is an outsourced pharma solutions company: It outsources R&D for pharmaceutical companies, whereas Catalent outsources manufacturing. If this does turn from a strategic review to an operational review, there is no guarantee that he keeps his job.
Persons: Catalent, there's, Elliott, Steven Barg, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Johnson, Barg, Ryan, John Greisch, There's, Danaher, Alessandro Maselli, Ken Squire Organizations: Oral Technologies, Clinical, Pfizer, Rom Holdings, Bloomberg, Merck, Citrix Systems, Nielsen Holdings, Square, Veritas Capital, Syneos Health, 13D Locations: COOs, North America
☆ Investment consortium to buy Syneos Health in $7.1 bln deal
  + stars: | 2023-05-10 | by ( ) www.reuters.com   time to read: +1 min
May 10 (Reuters) - An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to buy Syneos Health Inc (SYNH.O), in a deal valued at $7.1 billion, including debt, the contract research firm said on Wednesday. Syneos said the consortium will pay about $43 per share in cash, which represents a premium of about 12% to the company's last close of $38.45. The deal comes at a time when Syneos faces challenges in winning new business, as many of its clients, which includes medium-sized biotechs, have cut spending as they have found it difficult to raise funding in a post-COVID-19 market downturn. Deal comes days after a private-equity groups including Warburg Pincus and Advent International agreed to buy Baxter International (BAX.N) biopharma solutions unit for $4.25 billion. Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
☆ Investment consortium to take Syneos private for $4.46 billion
  + stars: | 2023-05-10 | by ( ) www.reuters.com   time to read: +2 min
May 10 (Reuters) - An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to take Syneos Health Inc (SYNH.O) private for $4.46 billion, the contract research firm said on Wednesday. Syneos said the consortium will pay about $43 per share in cash, which represents a premium of about 12% to the company's last close of $38.45. The acquisition is valued at $7.1 billion including debt. Syneos, which helps pharmaceutical companies with clinical trials and marketing their drugs, currently carries a debt of nearly $3 billion. The company reported a total backlog of contracts of $9.83 billion, as of March 31, 2023, down from $11.63 billion at the end of the first quarter of 2022.
0 next >>
Total: 6